The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from the BRAVE-AA-PEDS study on adolescents with severe alopecia areata and the ...

The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla, approvals of new indications for existing Lilly medicines ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Crohn's disease, also known as ...

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug ...

In other Lilly news, the FDA recently approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. The drug is is now approved in the United States ...